Sunday, December 8, 2013
Link Between Epilepsy and MS
Multiple sclerosis (MS) and Epilepsy are two of the most common neurological conditions, and now researchers have found that having one may lead to higher risk for the other. English researchers used the entire population of England to create the largest study on this topic to date. These researchers found a significantly greater risk of developing epilepsy in patients with MS.
This study also showed that patients who exhibited epileptic symptoms first had a greater chance of being diagnosed with MS within 10 years. These researchers concluded that MS and epilepsy may occur together more often possibly because the lesions associated with MS act as a focus of an epileptic seizure. This study suggested that doctors should be aware of the connection between MS and epilepsy. The findings may also help researchers come up with additional theories related to the two diseases.
Hudson’s father and his brothers all have multiple sclerosis, or a type of neurodegenerative disorder which they classify as multiple sclerosis. He said two of them find relief through medical cannabis. After listening to their stories, he saw how it provides medical benefits when used in the right doses.
The Peace Naturals Project is one of only three licensed medical cannabis companies in Canada. Health Canada launched the Marijuana for Medical Purposes Regulations (MMPR) in June, making it possible for companies to produce and distribute marijuana under strict guidelines. Peace Naturals Project founder and CEO Mark Gobuty created the project in 2010 after watching his parents suffer through illnesses on prescription painkillers.
Advances in Stem Cell Research
Neural Precursors “Cure MS” in Mice
During a session at the this week’s World Stem Cell Summit in San Diego, an international research team described an “astonishing” experiment in which a mouse model of multiple sclerosis was able to virtually totally recover and move normally after being transplanted with human neural precursor cells (hNPC). The scientists were able to show almost full recovery in the mice up to six months later.
The investigators, led by Jeanne Loring, Ph.D., from the Scripps Research Institute, included scientists from the University of California, Irvine and a group from Australia.
“Our goal was to demonstrate cell therapy for MS,” Dr. Loring told the audience.
According to Ronald Coleman, a graduate student working with Dr. Loring and who is at UC-Irvine, the team used mice infected with a neurotropic JHM variant of mouse hepatitis virus (JHMV) as a model for MS. They injected hNPCs derived from human pluripotent stem cells (hPSC) into the mice to explore treatment options for the disease.
The results were indeed astonishing, said Dr. Loring. Non-control mice were able to move about in a manner that can be described as consistent and long lasting. T-cell proliferation was reduced and T regulatory cell induction took place. The spinal cords of the mice not only did not undergo further demyelination but actually exhibited remyelination. The control mice dragged their legs around when they tried to move.
Governmental plan should improve MS care for rural patients, says Alberta Health minister
Alberta's minister of health has promised to improve services for those suffering from MS who live in rural areas of the province.
The provincial government announced Nov. 25 a plan to improve medical care and invest in research for the sake of the nearly 14,000 Albertans who live with multiple sclerosis. The Way Forward: Alberta's Multiple Sclerosis Partnership is a plan that's been in the works for the past five years, according to the governmental relations director for the MS Society of Alberta and Northwest Territories. It's centred on five recommendations to improve healthcare resources to support patients as well as develop education about the disease.
"Many people in the Hinton area would come to Edmonton [for treatment]," Kelndorfer said. "One of the things the MS Society has looked at is doing mobile clinics, bringing neurologists out to the rural areas." The neurologist, funded through Alberta Health Services, could also update the health professionals in the community about what's happening in MS research, she added.
My MS is Not "My Fault"
Georgia Insurance Commissioner Ralph Hudgens has accused people with pre-existing conditions of being at fault, and said that he would do everything in his power to be an "obstructionist" of Obamacare. We can't trust him to do his job; it's time for him to resign.
I’m Keisha Kuma, a mother of three from Georgia, and I have Multiple Sclerosis (MS). Insurance companies use to label me a pre-existing condition. And now, Georgia Insurance Commissioner Ralph Hudgens is telling me this disease is “my fault.” He really said that someone with an undetectable, debilitating and chronic disease is at fault. He actually compared my disease to a car wreck:
A pre-existing condition would be you then calling up your insurance agent and saying, 'I would like to get collision insurance coverage on my car.' And your insurance agent says, 'Well, you never had that before. Why would you want it now?' And you say, 'Well, I just had a wreck, it was my fault and I want the insurance company to pay to repair my car.' And that's the exact same thing on pre-existing insurance."
He tried to walk back his comments claiming it was a “poor analogy” but clearly he just doesn’t get it. He’s the same guy who said he would do everything in his power to be an “obstructionist” of Obamacare.
Life looks real rosy for battling Patricia
A FLORIST has expanded her business - and it’s proof that her eight-year fight with multiple sclerosis just won’t get in the way.
Patricia Purvis, 29, has moved into a shop in Wynyard Road in Hartlepool just months after starting her company Floral Whispers in the indoor market hall of the Middleton Grange Shopping Centre. She told Business Update: “Ever since I started working for myself my health has improved. I am not just sitting around and moping at home. I am out working and I am a lot happier.”
Patricia quit her career in the health service after suffering blurred vision and being diagnosed with MS at 21. But her determined spirit meant she would not let the condition get her down.
She used the time while she was recuperating to consider her options and decided to go for a career change. It led to the formation of Floral Whispers which is going from strength to strength, said Patricia. She and partner Mark Arnold, 34, part own the business. As well as flowers, the business also has its own app called The Bad Boyfriend Club.
Dependent Diseased Individuals
Suffering from multiple sclerosis, an inflammatory disease, results in many debilitating symptoms including spasticity, which the Sativex Independent Thinking ad campaign targets. Conceived and executed by Langland, an ad agency based in the United Kingdom, the Sativex Independent Thinking ad campaign was art directed by Andrew Morley with creative direction by Andrew Spurgeon and photography by Spencer Murphy. It depicts people suffering from spasticity going about daily activities such as brushing teeth and drinking coffee with the help of another person. It is a sad reality, but the Sativex drug hopes to help.
EHR Promotes Better Understanding of Multiple Sclerosis
Researchers at Vanderbilt University Medical Center have used natural language processing technology in an electronic medical records system to identify patients with multiple sclerosis and collect data on traits of their disease course.
Many studies have identified individuals serving as cases and controls for disease status using EMR data, the study notes. “This is one of the first studies to focus on specific traits of a disease by text mining of the EMR. A few other studies have used text mining approaches to extract blood pressures, pacemaker implantations and left ventricular ejection fractions as a marker of heart failure. We have shown that detailed clinical information valuable to research studies is recorded in medical records of individuals with MS, and that this information can be extracted in a highly reliable manner.”
15 STUDIES IN SUNDAY'S NEWS
PLUS: 501 new Studies we posted from 11/1 to Saturday 12/7 Start at the Bottom!
OTC Meds May Prevent Marijuana-Induced Memory Problems
"Our results suggest that the unwanted side effects of cannabis could be eliminated or reduced, while retaining its beneficial effects, by administering a COX-2 inhibitor along with THC for the treatment of intractable medical conditions," Dr. Chen summarized.
Autoimmune T-Cell Reactivity to Myelin Proteolipids and Glycolipids in Multiple Sclerosis.
this review considers the question of what would be required to prove a definite role for autoreactivity against proteolipids and glycolipids in the pathogenesis of MS.
Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.
Changes in the blood lymphocyte composition probably both mediate and reflect the effects of natalizumab treatment in multiple sclerosis, with implications for treatment benefits and risks.
Our data confirms that natalizumab treatment increases the number of lymphocytes in blood, likely mirroring the expression of VLA-4 being highest on NK and B cells. This finding supports reduction of lymphocyte extravasation as a main mode of action, although the differential effects on subpopulation composition suggests that cell-signalling may also be affected. The systemic increase in T cell responsiveness reflects the increase in numbers, and while augmenting anti-infectious responses systemically, localized responses may become correspondingly decreased.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
The validation of these findings in the clinic might help to better understand the cause of the emotional and psychological burden of patients suffering MS or other autoimmune diseases. Most importantly our study suggests novel therapeutic venues for the treatment of the emotional changes associated with autoimmunity.
Erythrocyte membrane Fatty acids in multiple sclerosis patients and hot-nature dietary intervention with co-supplemented hemp-seed and evening-primrose oils.
We concluded that Hot-nature dietary intervention with co-supplemented hemp seed and evening primrose oils caused an increase PUFAs in MS patients and improvement in the erythrocyte membrane fatty acids composition. This could be an indication of restored plasma stores, and a reflection of disease severity reduction.
Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Although MRI, CSF and pathologic examination help in differential diagnosis of the mass lesions, close follow-up is still crucial for the definite diagnosis. A higher MS conversion rate was found in patients with a younger TDL onset age.
Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders.
Recently, the International Paediatric Multiple Sclerosis Study Group (IPMSSG) definitions for the diagnosis of immune-mediated acquired demyelinating syndromes (ADS) of the central nervous system, including paediatric multiple sclerosis (MS), have been revised. MS diagnosis can be made reliable and early using the 2012 IPMSSG consensus definitions. This is beneficial for adequate counselling of children and their families and for early treatment possibilities.
Analysis of CYP27B1 in multiple sclerosis.
he analysis of genetic variability in CYP27B1 and its effect on risk of multiple sclerosis (MS) has yielded conflicting results. Here we describe a study to genetically characterize CYP27B1 and elucidate its role on MS risk in the Canadian population. Sequencing CYP27B1 failed to identify mutations known to cause loss of enzymatic activity, however genotyping of p.R389H in cases and controls identified the mutation in one multi-incident family (allele frequency=0.03%) in which the p.R389H mutation segregates with disease in five family members diagnosed with MS, thus providing additional support for CYP27B1 p.R389H in the pathogenicity of MS.
Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
In recently completed randomized trials in RRMS, treatment with daclizumab monotherapy compared with placebo resulted in clinically meaningful and statistically significant reductions in relapses, active lesions on brain MRI and slowing of disability progression. A large Phase III trial in RRMS is ongoing.
Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica.
Synaptic Plasticity and PDGF Signaling Defects Underlie Clinical Progression in Multiple Sclerosis.
Association between multiple sclerosis and epilepsy: large population-based record-linkage studies.
Multiple sclerosis (MS) and epilepsy are both fairly common and it follows that they may sometimes occur together in the same people by chance. We sought to determine whether hospitalisation for MS and hospitalisation for epilepsy occur together more often than expected by chance alone. MS and epilepsy occur together more commonly than by chance. One possible explanation is that an MS lesion acts as a focus of an epileptic seizure; but other possibilities are discussed. Clinicians should be aware of the risk of epilepsy in people with MS. The findings may also suggest clues for researchers in developing hypotheses about underlying mechanisms for the two conditions.
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
Present and future of fMRI in multiple sclerosis.
As shown in brain studies, these investigations have detected increased recruitment in MS patients compared with healthy controls. At present, fMRI is a useful research tool, and reliable analysis and display methods have been developed. Future perspectives include development of fMRI paradigms for patients with MS-related disability and application of this technique in longitudinal studies to define the temporal evolution of functional cortical changes in different MS phenotypes as well as the effects of various therapeutic approaches on central nervous system plasticity.
Decoding multiple sclerosis: an update on genomics and future directions.
Ongoing efforts to fully characterize the repertoire of genes that predispose to MS and modulate its presentation is discussed. Functional characterization of even a moderate genetic effect on MS pathogenesis by a known gene or group of genes can assist in elucidating fundamental mechanisms of disease expression and yield important therapeutic opportunities.
501 STUDIES FROM 11/1 to Saturday 12/7 are below:
Saturday, December 7, 2013
Multiple Sclerosis Clinician-Scientist Development Award Winner Announced
“I am honored to have this opportunity to do research in MS with clinical applications and multiple potential future directions, while learning more about neuro-immunology,”
The Foundation of the Consortium of Multiple Sclerosis Centers (FCMSC) announced today that Rachel Ventura, MD, PhD, of New York University School of Medicine, is the first recipient of the FCMSC/EMD Serono Donald W. Paty Clinician-Scientist Development Fellowship Award. The award was created to meet the unique educational and developmental needs of translational Multiple Sclerosis (MS) research and to bridge the gap between basic and clinical science and its application to MS clinical care.
Community teams up to build service dog center
Having a service dog, like her yellow Labrador, Linden, gives her more independence, Jill said, explaining why the couple encouraged the nonprofit’s development here to help more people.
Certified assistance dogs can make life with a disability much easier, but obtaining these dogs in Wyoming can be difficult. So, multiple businesses and individuals in Cheyenne recently joined together to build a facility for K9s 4 Mobility to train more certified assistance dogs for people with disabilities.
The nonprofit, located east of Cheyenne, places guide dogs with people who are blind or visually impaired, service dogs for people who have a physical disability and social-service dogs for professionals such as an occupational therapist working in a school setting with children who have mental or physical disabilities.
Read more »
Multiple sclerosis pill to replace daily injections could soon be available on NHS
A pill to help multiple sclerosis sufferers cope with their condition may soon be available on the NHS.
Current treatment is by regular injections, but the National Institute for Health and Care Excellence has approved new drug teriflunomide, which would be taken daily as a tablet.
More than 100,000 people in the UK have MS, a chronic neurological condition which affects the brain and spinal cord, causing problems with muscle movement, balance and vision.
Nick Rijke, of the MS Society, said: "This is very good news for people with relapsing forms of MS. Ninety per cent of people with MS want an alternative to treatments by regular injection and now, at last, there is a first-line treatment available.
“Teriflunomide offers a similar treatment effect to the current injectable therapies, but for many people will be much easier to live with because it’s a pill.”
15 STUDIES IN SATURDAY'S NEWS
PLUS: 486 new Studies we posted from 11/1 to Friday 12/6 Start at the Bottom!
[Brain metabolism in multiple sclerosis: effects of neurotrophic therapy.]
[Differential diagnosis of multiple sclerosis with pediatric onset: the experience of the Moscow Division for treatment of children and adolescents with multiple sclerosis.]
[Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis.]
Patients who did not receive DMD had more relapses to the 3rd and 6th months after delivery. In conclusion, the use of DMD before the pregnancy is an important factor for prevention of relapses during pregnancy and after delivery.
Guideline for the diagnosis and management of multiple sclerosis in children.
The International Paediatric MS Study Group (IPMSSG) was formulated to clarify the diagnostic and therapeutic dilemmas in this population. This guideline was adapted from the International Paediatric Multiple Sclerosis Study Group guideline and endorsed by PANDA, South Africa.
Depression as a predictor of occupational transition in a multiple sclerosis cohort.
Adjustments for ambulation status, physical and mental quality of life composite scores and fatigue impact attenuated or eliminated the association. While depression commonly occurs around the time of occupational transitions in MS, it does not appear to be an independent or direct cause of such transitions.
Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis.
Effects of Multiple Sclerosis on Female Sexuality: A Controlled Study.
Sexual functions are negatively affected in MS women. Sexual functions in MS women seem to be associated with enhanced disability, pain, duration of the disease, and degree of concomitant depression. Therefore, women with MS should also be evaluated in terms of sexual function during routine follow-ups. Gumus H, Akpinar Z, and Yilmaz H. Effects of multiple sclerosis on female sexuality: A controlled study. J Sex Med
MicroRNA Expression Aberration in Chinese Patients with Relapsing Remitting Multiple Sclerosis.
Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
Consequences of perinatal bisphenol A exposure in a mouse model of multiple sclerosis.
These results demonstrate the effect of BPA on the trajectory of TVID, and illustrate how multiple factors collectively influence autoimmune disease.
Clinically meaningful performance benchmarks in MS: Timed 25-Foot Walk and the real world.
Identify and validate clinically meaningful Timed 25-Foot Walk (T25FW) performance benchmarks in individuals living with multiple sclerosis (MS). Using a cross-sectional design, we identified 2 clinically meaningful T25FW benchmarks of ≥6 seconds (6-7.99) and ≥8 seconds. Longitudinal and larger studies are needed to confirm the clinical utility and relevance of these proposed T25FW benchmarks and to parse out whether there are additional benchmarks in the lower (<6 seconds) and higher (>10 seconds) ranges of performance.
Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.
To investigate the potential of standardized exercise as a therapeutic intervention for progressive MS, in a randomized-controlled pilot trial. This study indicated that aerobic training is feasible and could be beneficial for patients with progressive MS. Larger exercise studies are needed to confirm the effect on cognition.
Central auditory processing and word discrimination in patients with multiple sclerosis.
Results of the present study showed that patients with MS had defect in aspects of central auditory processing consisting of temporal resolution, auditory pattern and the memory for auditory task and difficulty in discrimination of speech in noisy environment that are related to the involvement of central nervous system.
Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model.
These results suggest that inflammation-mediated alterations in the lower lumbar cord change the homeostasis of the spinal cord and demonstrate that ultrahigh-field MRI enables the detection of previously invisible pathological alterations in EAE.
Automated extraction of clinical traits of multiple sclerosis in electronic medical records.
The clinical course of multiple sclerosis (MS) is highly variable, and research data collection is costly and time consuming. We evaluated natural language processing techniques applied to electronic medical records (EMR) to identify MS patients and the key clinical traits of their disease course. This collection of clinical data represents one of the largest databases of detailed, clinical traits available for research on MS. This work demonstrates that detailed clinical information is recorded in the EMR and can be extracted for research purposes with high reliability.
486 STUDIES FROM 11/1 to Friday 12/6 are below:
Actress Teri Garr's star was shooting upward in Hollywood in the early '80s, when she noticed troubling symptoms. She revealed her MS diagnosis to the world in 2002. She urges people newly diagnosed with MS to learn all they can about the illness. The disease affects each person differently. Plus, doctors have many treatments to help hold the disease in check.
MS hasn't stopped singer-songwriter Tamia Hill from sharing her gift of music. She's recorded four albums since her diagnosis at age 28. Hill says she has good days and bad days, and finds it helpful to keep a positive attitude. Hill also works to raise public awareness of MS -- and stays busy raising her family with her husband, NBA star Grant Hill.
"I think it's an interesting preliminary study that has potential [applications] for people living with MS,'' says Bruce Bebo, PhD. He is associate vice president of discovery research for the National Multiple Sclerosis Society. He was not involved in the study.
A protein found in HDL, or ''good,'' cholesterol may help protect against the effects of multiple sclerosis, according to new research. In the study, patients with MS had much lower levels of the protein than did healthy people, says study researcher Lidia Gardner, PhD. She is an assistant professor of neurology at the University of Tennessee Health Science Center. Those with more severe forms of MS, known as progressive, had even lower levels of the protein than those with a milder form called relapsing-remitting. The protein is known as ApoA1.
Last year’s research done by Gladstone Institute Investigator Katerina Akassaglou, Ph.D. and her team had revealed an important start in the beginning stages of multiple sclerosis (MS) and Wednesday’s paper shows what they did with those discoveries. They were able to show, last year, that MS begins with the break down of the blood brain barrier (BBB); it physically separates from blood circulation thereby allowing fibrogen to seep into the brain. The protein thrombin then coverts fibrogen into fibren, a fibrous substance, formed in the coagulation of the blood, and, since fibren aren’t suppose to be in the brain; it triggers the body’s immune response.
Read more »
Karin Heckman, assistant professor of biology, and William E. DeCoteau, associate professor of psychology, were lead authors on a research paper, published in a scientific journal, that examined cerium oxide nanoparticles and their ability to alleviate the symptoms of multiple sclerosis.The article, titled “Custom Cerium Oxide Nanoparticles Protect Against a Free Radical Mediated Autoimmune Degenerative Disease in the Brain,” was published this month in ACS Nano, a publication of the American Chemical Society.
Ana Y. Estevez, associate professor of biology and psychology, and Joseph S. Erlichman, professor and R. Sheldon ’68 and Virginia H. Johnson Chair of Science and co-chair of the Department of Biology, were also listed as authors in the publication.
Read more »
Friday, December 6, 2013
THIS IS MY 1ST COLUMN! IT'S ABOUT FINDING TRUE LOVE & MY MS & AN INTRO ME!
Well I finally get to have my voice heard and be a Columnist on MSnewsChannel.com First of all I'll start with an introduction.
My name is Debbie and I just turned 41. I was diagnosed at the age of 24 in May '97 but can trace back symptoms to '86 when I was 13. I started out on Avonex. I am married to my wonderful husband Stephen. Our anniversary is the 16th of December and it will be are 13th. Marrying in 2000 makes it so much easier for an MS'er with brain fog to know what anniversary year it is.
He moved to be with me in Northern, VA from Wales, UK. We met online in '98 and I was completely bedridden when he came to visit me in July of '99. That's when he proposed to me. I was like Quadriplegic almost. Could only move my hands and come to find out that not only did I get the 00.1% alopecia that can get from Avonex but my body was allergic to Interferon. Stephen came back in September and I was able to get in my wheelchair and go with my Mom to pick him up.
You could say it was God, love, or Copaxone that got me better and out of bed but I say a bit of all 3. We lived with my Mother for the first 3 1/2 years of marriage until we could find an apartment of our own and we did in 2004 and have been living here ever since.
I'm so thankful for Stan & Stan's Angels He's the greatest in finding out important information on MS as well get other MS'ers to get to chat with one another and be a cyber voice for happy times, sad times, and just to plain rant. I first found him on MySpace and I went to Facebook because my in-laws were on there and Stan joined Facebook too. He rocks and you can't help but love him.
Do we have kids? Unfortunately No. I always wanted them but....
Read more »
15 STUDIES IN FRIDAY'S NEWS
PLUS: 471 new Studies we posted from 11/1 to Thursday 12/5 Start at the Bottom!
Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment. Most studies of cortical lesions have focused on autopsy findings in patients with long-standing, chronic, progressive multiple sclerosis, and the noninflammatory nature of these lesions has been emphasized. Magnetic resonance imaging studies indicate that cortical damage occurs early in the disease.
Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration
Macular oedema typically results from blood–retinal barrier disruption. It has recently been reported that patients with multiple sclerosis treated with FTY-720 (fingolimod) may exhibit macular oedema. Multiple sclerosis is not otherwise thought to be associated with macular oedema except in the context of comorbid clinical uveitis. Despite a lack of myelin, the retina is a site of inflammation and microglial activation in multiple sclerosis and demonstrates significant neuronal and axonal loss.
FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+CD25high T cells in multiple sclerosis
Many promising MRI approaches for research or clinical management of multiple sclerosis (MS) have recently emerged, or are under development or refinement. Advanced MRI methods need to be assessed to determine whether they allow earlier diagnosis or better identification of phenotypes. Improved post-processing should allow more efficient and complete extraction of information from images.
Magnetic resonance imaging (MRI) of lesions in the brain may be the best current candidate for a surrogate biological marker of clinical outcomes in relapsing remitting multiple sclerosis (MS), based on its role as an objective indicator of disease pathology. No biological surrogate marker has yet been validated for MS clinical outcomes. Confidence intervals for correlations between CELs and MS relapses exclude the possibility that CELs can be a good surrogate for relapses over the time scales we investigated. Further exploration of surrogacy between MRI measures and MS clinical outcomes may require improved datasets, the development of MRI techniques that couple better to clinical disease, and the ability to test a wide range of imaging- and clinically-based hypotheses for surrogacy.
Presenting evidence-based health information for people with multiple sclerosis: the IN-DEEP project protocol
Increasingly, evidence-based health information, in particular evidence from systematic reviews, is being made available to lay audiences, in addition to health professionals. Research efforts have focused on different formats for the lay presentation of health information. However, there is a paucity of data on how patients integrate evidence-based health information with other factors such as their preferences for information and experiences with information-seeking. The aim of this project is to explore how people with multiple sclerosis (MS) integrate health information with their needs, experiences, preferences and values and how these factors can be incorporated into an online resource of evidence-based health information provision for people with MS and their families.
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells.
A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis
White matter (WM) and grey matter (GM) brain damage in multiple sclerosis (MS) is widespread, but the extent of cerebellar involvement and impact on disability needs to be clarified. These findings indicate reduced fibre coherence in the main cerebellar connections, and link damage in the whole cerebellar WM, and, in particular, in the superior cerebellar peduncle, to motor deficit in PPMS.
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify key priority areas for research. A collaborative was convened by volunteer and staff leaders from several MS societies with the mission to expedite the development of effective disease-modifying and symptom management therapies for progressive forms of multiple sclerosis.
Clinically Isolated Syndromes Suggestive of Multiple Sclerosis: An Optical Coherence Tomography Study
Optical coherence tomography (OCT) is a simple, high-resolution technique to quantify the thickness of retinal nerve fiber layer (RNFL), which provides an indirect measurement of axonal damage in multiple sclerosis (MS). This study aimed to evaluate RNFL thickness in patients at presentation with clinically isolated syndromes (CIS) suggestive of MS.
Susac syndrome, a rare but probably underdiagnosed combination of encephalopathy, hearing loss, and visual deficits due to branch retinal artery occlusion of unknown aetiology has to be considered as differential diagnosis in various conditions. Particularly, differentiation from multiple sclerosis is often challenging since both clinical presentation and diagnostic findings may overlap. Optical coherence tomography is a powerful and easy to perform diagnostic tool to analyse the morphological integrity of retinal structures and is increasingly established to depict characteristic patterns of retinal pathology in multiple sclerosis. Against this background we hypothesised that differential patterns of retinal pathology facilitate a reliable differentiation between Susac syndrome and multiple sclerosis.
471 STUDIES FROM 11/1 to Thursday 12/5 are below:
Innovative approach in animal models could one day serve as early indicator of multiple sclerosis
For some, the disease multiple sclerosis (MS) attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages - even before the onset of physical signs.
In a new study from the laboratory of Gladstone Investigator Katerina Akassoglou, PhD, scientists reveal in animal models that the heightened activity of a protein called thrombin in the brain could serve as an early indicator of MS. By developing a fluorescently labeled probe specifically designed to track thrombin, the team found that active thrombin could be detected at the earliest phases of MS - and that this active thrombin correlates with disease severity. These findings, reported online in Annals of Neurology, could spur the development of a much-needed early-detection method for this devastating disease.
Read more »
Study provides first class 1 evidence for cognitive rehabilitation in MS
Kessler Foundation researchers published the results of the MEMREHAB Trial in Neurology, the medical journal of the American Academy of Neurology, providing the first Class I evidence for the efficacy of cognitive rehabilitation in multiple sclerosis (MS).
The article, Chiaravalloti N, Moore NB, Nikelshpur OM, DeLuca J: An RCT to treat learning impairment in MS. Neurology 2013(81), was released as an epub ahead of print on November 8. It was accompanied by an editorial: Filippi M, Rocca MA: Let's rehabilitate cognitive rehabilitation for MS. Neurology 2013(81):1-2.
Although disabling cognitive problems that affect functional performance and employment are common in persons with MS, there are very few evidence-based protocols for cognitive rehabilitation in MS.
Read more »
You Don’t Know Jack About MS: Jack Osbourne's New Campaign
NORTH WALES, Pa., Dec. 4, 2013--(BUSINESS WIRE)--Television host and film and TV producer, Jack Osbourne, is helping to raise awareness about multiple sclerosis (MS), through a new campaign called You Don’t Know Jack About MS™. The online documentary series, sponsored by Teva Pharmaceuticals, chronicles Jack Osbourne and his life with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, in which a person experiences episodes of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs.
Read more »
SPREADING HOPE ONE PHOTO AT A TIME
Perhaps you've seen Micheala Johanson tooling around Akron and Cleveland in her power wheelchair. Camera on board, she rides the bus, gets lifts from pals, or drives her chair as far as she can _ praying that her battery won't run out of juice before she makes it home to Barberton, Ohio READ MORE
CHERRY HILL, N.J., Dec. 4, 2013 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) announces a national call for entries for the Swim for MS – Why I Swim campaign, through a collaborative sponsorship with Genzyme, a Sanofi company. Individuals with multiple sclerosis (MS) who currently swim or participate in water-based exercise programs are encouraged to visit SwimForMS.org and share their personal story about how water activities have impacted their lives. Why I Swim is just the beginning of a larger effort from MSAA and Genzyme to raise awareness and understanding of water-based exercise programs as a positive wellness opportunity for the MS community. In addition to the Why I Swim campaign, MSAA is developing a variety of tools including print, video, and web-based educational materials on aquatic exercise and MS.The Swim for MS – Why I Swim campaign will increase awareness and education about the value of swimming for people living with MS. Swimming is known to be one of the best exercises for all age groups and body types. It can be especially good for people with chronic conditions, such as MS. Research on the effects of aquatic therapy for individuals with MS has demonstrated benefits such as improved flexibility, muscle strength, mobility function, and quality of life.
"Our new and long-term investors appreciate the value proposition of MSPrecise – to give physicians superior tools and insights when they are evaluating patients with neurological dysfunction at first clinical presentation. With the growing portfolio of therapeutics now available for MS, it is critical that we achieve similar innovations in our diagnostic methods to ensure patients obtain early and appropriate interventions," said Larry Tiffany, President and CEO of DioGenix.GAITHERSBURG, Md., Dec., 2013 /PRNewswire/ -- DioGenix, Inc. announced today that it raised $3.2 million in a private financing consisting of new individual investors and returning investors including life sciences fund Nerveda, LLC. The financing follows recent interim results from a prospective clinical trial of DioGenix' MSPrecise®, a next-generation sequencing assay, which continues to show that it can accurately identify patients with multiple sclerosis (MS) at first clinical presentation.
The financing will support the completion of the largest prospective clinical diagnostic trial of its kind in MS. This study should validate the performance of MSPrecise in a population of patients being evaluated for MS and a variety of other neurological diseases. DioGenix has also established a new central laboratory that will serve as the basis for the company's future commercialization of MSPrecise upon CLIA licensure.
DioGenix also announced that it has expanded its licensing arrangement with the University of Texas Southwestern Medical Center (UTSW) to provide exclusivity to core technology related to MSPrecise for MS and other neurological diseases.
"DioGenix exemplifies an ideal investment for Nerveda, as MSPrecise could significantly improve upon existing methods for diagnosing multiple sclerosis and other neurological diseases. DioGenix has achieved important development and business milestones that pave the way for its lead product to achieve additional clinical progress in 2014," said Cam Gallagher, Chairman of DioGenix and President of Nerveda, a private life science fund.
"Our new and long-term investors appreciate the value proposition of MSPrecise – to give physicians superior tools and insights when they are evaluating patients with neurological dysfunction at first clinical presentation. With the growing portfolio of therapeutics now available for MS, it is critical that we achieve similar innovations in our diagnostic methods to ensure patients obtain early and appropriate interventions," said Larry Tiffany, President and CEO of DioGenix.
Read more »
Thursday, December 5, 2013
DEA RAIDS MEDICAL MARIJUANA DISPENSARIES IN DENVER
DEA and IRS agents backed up by Denver and other state and local law enforcement raided a number of Denver area medical marijuana dispensaries and grow operations Thursday. The US Attorney for Colorado’s office confirmed the raids were taking place.
“The Drug Enforcement Administration, Internal Revenue Service Criminal Investigations, the Denver Police Department and state and local law enforcement are today executing lawfully obtained search warrants and seizure warrants,” said Jeff Dorschner, spokesman for the US Attorney for Colorado’s office in a Thursday statement.
Read more »
'I thought I'd be out in week five': Jack Osbourne is proud to come third place in DWTS after battling multiple sclerosis
Tuberculosis Vaccine May Help Prevent Multiple Sclerosis
People with early signs of multiple sclerosis who were treated with a vaccine used to prevent tuberculosis were less likely to get sick than patients who weren’t vaccinated, according to an early study.
Researchers recruited 73 people who had a first episode suggestive of multiple sclerosis, an autoimmune disease that can be difficult to diagnose. Five years later, almost 60 percent of those given the TB vaccine hadn’t developed multiple sclerosis compared with a third of the group that received a placebo instead, according to a study today in the journal Neurology.
The research supports the hygiene hypothesis, which suggests people have become so clean they suppress natural development of the immune system, leading to a surge in diseases in which these infection-fighting cells attack healthy tissue in the body, said Dennis Bourdette, who wrote an editorial accompanying the study. The tuberculosis vaccine may wake the regulatory arm of the immune system, helping to steer the body’s killer cells away from the neurons it attacks in MS.
“The interesting thing was that the single injection affected the course of the recipients for up to five years after they received it,” Bourdette, the chairman of neurology at Oregon Health and Science University in Portland, said in a telephone interview.
About 2.3 million people worldwide have multiple sclerosis, according to the National Multiple Sclerosis Society, a patient advocacy group. The disease destroys neurons when the immune system mistakenly attacks the protective coating on nerve fibers, disrupting the body’s communications. Eventually, this leads to blurred vision, poor balance and coordination, problems with speaking, tremors, fatigue and paralysis. READ FULL ARTICLE HERE
I had never eaten organ meats in my life, even though my mom used to make chopped chicken liver regularly. I didn’t like the taste or the thought of eating icky vital organs. Then I encountered the work of Terry Wahls, MD, a doctor who has recovered significantly from multiple sclerosis. She did it through a landslide of vegetables and fruits (nine plate-sized servings a day) and organ meats twice a week.
I was with her on the vegetables. I like them, even though nine plates a day sounds a bit crazy. I figured I would give the organ meats a pass.
But I’m serious about trying to get out of this wheelchair. I’m doing some other treatments too, so it seemed like time to give it my best efforts. I looked into organ meats and this is what I found.
Dr. Andrew Weil writes,
Liver is packed with vitamins. A four-ounce portion of calves’ liver gives you more than 1600% of the daily value of vitamin A and hundreds of times the daily values of vitamins B12 and B2 (riboflavin) as well as lots of iron, zinc, folate, and other essential nutrients.
Read more »
JERUSALEM & OSAKA, Japan--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva’s innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan. Teva and Takeda are currently working on further agreements in connection with the implementation of this license.
Developed by Teva, glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. It is considered standard treatment for relapsing-remitting multiple sclerosis, and is now approved in 55 countries worldwide. Teva’s glatiramer acetate is designated as an orphan drug in Japan, and currently is under development as an Unapproved New Drug by Teva Pharmaceutical K.K., a subsidiary of Teva, at the request of the Japanese Ministry of Health, Labor and Welfare.
Under the terms of the agreement, Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application for registration of glatiramer acetate in Japan. The financial details of the agreement are confidential.
Teva and Takeda will work under close cooperation so that both parties can provide a new treatment option to patients with multiple sclerosis in Japan as early as possible, where the current available therapies are still limited. READ FULL ARTICLE HERE
15 STUDIES IN THURSDAY'S NEWS
PLUS: 456 new Studies we posted from 11/1 to Wednesday 12/4 Start at the Bottom!
A Transdermal Myeloid Peptide Patch to Treat MS
Although antigen-specific autoimmunity is thought to play a critical role in the pathogenesis of multiple sclerosis, all currently available therapies reduce global immune function without targeting the specific antigens involved. The goal of this 1-year, double-blind, placebo-controlled cohort study was to examine the efficacy and safety of transdermally applied myelin peptides as antigen-specific therapy in multiple sclerosis.
Sjögren Syndrome: An A-to-Z Update
A steady growth in the number of abstracts and sessions devoted to Sjögren syndrome is apparent over the past decade of ACR meetings. It is encouraging that many pharmaceutical companies are now expressing interest in Sjögren syndrome as a therapeutic target. The dearth of effective therapies for systemic manifestations of Sjögren syndrome contrasts with the large number of therapies for rheumatoid arthritis and studies for psoriatic arthritis. Multiple sclerosis and fibromyalgia have also benefited from recently approved therapies.
Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis.
Approximately half of all patients with multiple sclerosis (MS) experience cognitive dysfunction, including learning and memory impairment. Recent studies suggest that hippocampal pathology is involved, although the mechanisms underlying these deficits remain poorly understood. Evidence obtained from a mouse model of MS, the experimental autoimmune encephalomyelitis (EAE), suggests that in the hippocampus of EAE mice long-term potentiation (LTP) is favoured over long-term depression in response to repetitive synaptic activation, through a mechanism dependent on enhanced IL-1β released from infiltrating lymphocytes or activated microglia.
The risk of Bipolar Disorders in Multiple Sclerosis.
The aim was to determine the risk of Mood Disorders (MD), particularly Bipolar Disorders (BD), in Multiple Sclerosis (MS) using standardized psychiatric diagnostic tools. This study was the first to show an association between BD and MS using standardized diagnostic tools and a case-control design. The results suggest a risk of under-diagnosis of BD (particularly type II) in MS and caution in prescribing ADs to people with depressive episodes in MS without prior excluding BD. The association between auto-immune degenerative diseases (like MS) and BD may be an interesting field for the study of the pathogenic hypothesis.
A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility.
he aim of this study was to determine whether the functional chemokine receptor 5 delta32 (CCR5-Δ32) polymorphism is associated with multiple sclerosis (MS) susceptibility.
Long-term effects of dalfampridine in patients with multiple sclerosis.
Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9-12months. Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS.
Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment.
his study was aimed at (i) comparison of the usefulness of serum protein oxidation parameters for assessment of oxidative stress (OS) in multiple sclerosis (MS), and (ii) comparison of OS in MS patients subject to various therapies. Elevated glycophore level was noted in relapsing-remitting (RRMS) patients without treatment and patients treated with interferons β1a and β1b (10.33±3.27, 8.02±2.22 and 8.56±2.45 vs control 5.27±0.73 fluorescence units (FU)/mg protein).
Cross-sectional area variations of internal jugular veins during supine head rotation in multiple sclerosis patients with chronic cerebrospinal venous insufficiency: a prospective diagnostic controlled study with duplex ultrasound investigation.
Normally, chronic cerebrospinal venous insufficiency (CCSVI) has been studied using echo-colour Doppler (ECD). Subjects are examined in the supine and sitting positions, in accordance with a static protocol without rotation of the head. A dynamic approach, to assess venous sizes with different degrees of head rotation, has only been performed to improve jugular venous catheterisation. These echographic studies have suggested that head rotation to the contralateral side increases the cross-sectional area (CSA) of the internal jugular veins (IJVs) in supine subjects. Our goal was to evaluate the behaviour of CSA of the IJVs during supine head rotation in multiple sclerosis (MS) patients with CCSVI, compared to healthy controls (HCs). A dynamic ECD approach allowed us to detect IJVs with a significant increase in their CSAs during head rotation, but only in MS subjects. This feature, most likely the expression of congenital wall miopragia, could be secondary to dysregulation of collagen synthesis, but further histochemical studies will be needed to confirm this hypothesis.
Assessment of upper limb motor function in patients with multiple sclerosis using the Virtual Peg Insertion Test: A pilot study.
Quantifying and tracking upper limb impairment is of key importance to the understanding of disease progress, establishing patient-tailored therapy protocols and for optimal care provision. This paper presents the results of a pilot study on the assessment of upper limb motor function in patients with multiple sclerosis (MS) with the Virtual Peg Insertion Test (VPIT). The test consists in a goal-directed reaching task using a commercial haptic display combined with an instrumented handle and virtual environment, and allows for the extraction of objective kinematic and dynamic parameters.
A telerehabilitation program improves postural control in multiple sclerosis patients: a spanish preliminary study.
ostural control disorders are among the most frequent motor disorder symptoms associated with multiple sclerosis. This study aims to demonstrate the potential improvements in postural control among patients with multiple sclerosis who complete a telerehabilitation program that represents a feasible alternative to physical therapy for situations in which conventional treatment is not available.
Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis.
We provide a focused review of novel immunomodulatory approaches for the treatment of multiple sclerosis, the most common acquired inflammatory demyelinating disease of humans. The requirement for such a review was stimulated by the emerging application of novel oral medications and the need for the practicing physician to place these within the treatment paradigm.
A nine-year population-based cohort study on the risk of multiple sclerosis in patients with optic neuritis.
Patients with optic neuritis (ON) are at an increased risk of developing multiple sclerosis (MS), an illness that may result in physical dysfunction and short life expectancy. Information on the conversion rate to MS of patients with ON is essential in determining the impact of ON on the incidence of MS. Previous Taiwanese studies on the risk of MS in patients with ON were all hospital based, thereby limiting the generalizability of the findings.
Mood and coping in clinically isolated syndrome and multiple sclerosis.
Few studies have examined behavioural changes in the early phase of multiple sclerosis (MS). The aim of the study is to investigate mood alterations and to explore coping strategies regarding patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS). This study highlights transient mood alterations and an improving of adaptive coping over a period of time in patients with CIS and RRMS. Similar emotional reactions and coping in clinical subgroups suggest that these factors are independent from the type of information provided during the communication of the diagnosis.
Improvement of driving skills in persons with Relapsing-Remitting Multiple Sclerosis: a pilot study.
To determine the potential to improve driving-related skills using a simulator-based program in persons with Relapsing Remitting Multiple Sclerosis (RRMS). This pilot study demonstrates the potential of using a simulator to improve driving-related visual, cognitive, and on-road skills in individuals with RRMS, particularly those with EDSS > 3. Future randomized controlled trials with adequate power are needed to expand this field of study.
Group specific vein-atlasing: An application for analyzing the venous system under normal and multiple sclerosis conditions.
To create a group-specific vein-atlas based on healthy control subjects to visualize the average venous system under normal conditions and to compare the venous volume portion in multiple sclerosis (MS) lesions with that atlas. The developed vein-atlas shows the average venous system of a specific population and allows, therefore, the evaluation of the venous system of individual subjects.
456 STUDIES FROM 11/1 to Wednesday 12/4 are below:
Wednesday, December 4, 2013
Jody Corey-Bloom, M.D., PH.D Professor of Neurosciences Director of the UC San Diego MS Center University of California, San Diego
"SMOKING MARIJUANA CUTS SPASTICITY & PAIN THAT'S RESISTANT TO CONVENTIONAL TREATMENTS FOR MS PATIENTS"
A difference or two or more points is considered clinically meaningful on the 30-point Ashworth scale which covers mobility of elbows, hips, and knees, report Jody Corey-Bloom, M.D., Ph.D., and colleagues at UCSD. The researchers reported their findings online in CMAJ.
Besides the positive effects on spasticity, pain scores decreased by about 50 percent as well, the researchers reported. “We saw a beneficial effect of smoked cannabis on treatment-resistant spasticity and pain associated with multiple sclerosis among our participants,” Corey-Bloom said.
The findings regarding smoked marijuana support anecdotal evidence from many MS patients who say smoking the herb relieves spasticity, the researchers noted. About 400,000 pepole in the United States have MS.
The body naturally produces cannabinoids, a group of chemicals also found in marijuana. Studies have suggested that the cannabinoid receptors on our cells help regulate muscle spasticity, reports Amy Norton of Reuters.
Read more »
Can inhaled stem cells fix your brain?
In certain neurosurgical procedures, like fixing pituitary glands, surgeons can remove a tumor through the nose with minimal damage to surrounding tissue. It turns out, that passing things in the other direction—into the brain through an intranasal route—has many advantages too. Everything from drugs, proteins, and gene vectors, to stem cells, can now by administered in this way. The major question for today, is not so much what do these agents do, but where do they go once they are inside? StemGenex, a La Jolla-based company, has recently announced their new hopes for a treatment which could potentially address several neurological diseases. They are now offering a therapy for patients with multiple sclerosis in based on the intranasal delivery of mesenchymal stem cells.
The preferred medical term for act of snorting is insufflation. While insufflation is an obvious choice to deliver drugs to the sinuses or lungs, it is now appreciated that many bioactive agents can get much further than that. One major advantage of this method is the low barrier of entry through the mucous membranes into the bloodstream. Although some pro-drugs, like codeine, require absorption through the gut to pass to the liver where they can be metabolized into an active form, many other drugs are compromised by a digestive passage. What's more important though here for the brain, is that the normally-intact blood brain barrier can by bypassed either by slipping around the perineural sheath cells, or getting endocytosed and retrogradely transported along either the olfactory nerves, or the trigeminal nerves.
Read more »
This past August, the center put on its fourth annual Clinic Charity Classic golf tournament at City Park. By adding a raffle and charity concert the same weekend, the group pulled together more than $41,000 for the National MS Society. By the end of this month, the group's donations should total $54,628 for 2013. And to date, the medical marijuana dispensary chain has donated more than $102,500 to the charity, making it one of the top contributors in the Rocky Mountain region.
Of all the conditions that bring patients to The Clinic Medical Marijuana Centers, one is especially important to master grower Jay Price: multiple sclerosis. He knows which strains help the muscle pains and which strains help the eye spasms or the depression that often comes from battling the incurable disease. But helping a handful of patients find the right strain to ease their symptoms can only do so much, which is why for the last four years, the Clinic has been committed to fundraising for the national MS Society, quickly becoming one of the top donors in the region.
Read more »
Over the past decade, drug companies have become increasingly dependent on blockbuster drugs -- patented specialty drugs that generate more than $1 billion in sales annually.
However, when a major blockbuster loses patent protection, generic competition leaves a gaping hole in the top line, abruptly changing a company's greatest strength into its greatest liability. Let's take a closer look at five blockbuster drugs that will lose patent protection in 2014, and how four companies -- Teva Pharmaceutical (NYSE: TEVA ) , Eli Lilly (NYSE: LLY ) , Novartis (NYSE: NVS ) , and AstraZeneca (NYSE: AZN ) -- will be affected.
Terrible days ahead for Teva
Teva Pharmaceutical is best known for its generics business, but also owns a sizable large specialty pharmaceuticals business that accounts for 42% of its revenue.
Teva's biggest drug in its specialty portfolio is Copaxone, a blockbuster multiple sclerosis drug that generated $1.05 billion in sales last quarter -- half of the specialty pharma segment's revenue and 20% of Teva's total top line. Over the past four years, sales of Copaxone have steadily risen as the primary pillar of growth for Teva's top line.
However, Teva's key patent for Copaxone will expire in May 2014, opening the doors for generic competition. Mylan and Momenta Pharmaceuticals have already stated that their intent to release generic versions the moment Teva's patent expires. Generic Copaxone would be an excellent development for MS patients, who pay $40,000 for the drug annually, but it could be devastating to Teva's top line.
Detecting cognitive dysfunction in a busy multiple sclerosis clinical setting: A Computer generated approach
Lapshin H, et al. – This study aims to explore the effectiveness of a brief, computerized battery of tests in detecting cognitive differences between clinically isolated syndromes (CIS), relapsing–remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS) patients. The ability of this computerized cognitive battery to distinguish the progression of cognitive deficits across the entire multiple sclerosis disease spectrum from CIS through to SPMS enhances its construct validity. This finding, coupled with the battery's brevity (20 min) and ease of administration, highlights its potential utility in a busy clinic setting.
Go to Older News